Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

Neogenix Oncology, Inc. announced today that members of its scientific staff will present laboratory studies of NEO-101, a novel monoclonal antibody in development to diagnose and treat pancreatic and colorectal cancers. The presentation is scheduled at the American Association of Cancer Research (AACR) 102^nd Annual Meeting being held April 1-6, 2011 at the Orange County Convention Center, Orlando, FL, USA.

“Neogenix is committed to building our preclinical knowledge base, of both NEO-101 and its target molecule, which is critical to understanding the pathology biology behind these cancers”

NEO-101 (NPC-1C, or Ensituximab) is a chimeric monoclonal antibody being developed as a novel biological treatment for pancreatic and colorectal cancer and is currently in Phase I clinical trials at The Johns Hopkins University Hospital, Duke University Medical Center and North Shore University/Long Island Jewish Medical Center. NEO-101 is the first in the Neogenix pipeline of antibodies intended to target specific cancers. The NEO-101 target appears to be a variant of MUC5AC that is expressed specifically by human colon and pancreatic tumor tissues and cell lines that in testing to date, have only occasionally shown, minimal and weak cross-reactivity to certain normal GI tract tissues. The preclinical data to be presented includes in vitro mechanism of action, immunofluorescent cell staining, in vivo anti-tumor efficacy, bio-distribution, and toxicokinetic studies.

"Neogenix is committed to building our preclinical knowledge base, of both NEO-101 and its target molecule, which is critical to understanding the pathology biology behind these cancers," said Neogenix Chief Executive Officer, Philip M. Arlen, MD.

Poster Presentation Information:

Abstract Title: Pre-clinical studies of a novel antibody to treat pancreatic and colorectal cancers

Poster Session Date/Time: Immunology 6; Tuesday April 5^th at 1:00pm-5:00pm.

Permanent Abstract ID: 4584

Location: Exhibit Hall A4-C; Poster Session 31; Poster #26